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Biomonitoring and
Biomarker-Guided Therapy
The Next Step in Heart
Failure and Biomarker Research*
Alan Maisel, MD
San Diego, California
In an editorial several years ago surrounding the publication
of the BATTLE-SCARRED (NT-proBNP-Assisted
Treatment to Lessen Serial Cardiac Readmissions and
Death) trial (1,2), I surmised that in the not too distant
future, biomarker-guided therapy might allow physicians to
personalize heart failure (HF) treatment toward the better-
ment of patients. Holding up the “biomarker bar” were the
natriuretic peptides (NPs). Excellent surrogates for ventric-
ular stretch and volume overload, they appeared ideally
suited as a means to drive individual therapy for acute (“wet
B-type NP [BNP]”) and chronic (“dry BNP”) HF (3–5).
See page 1881
Wet BNP represents acutely synthesized BNP or proBNP
that occurs with ventricular stretch from volume overload,
and dry BNP represents ventricular remodeling, fibrosis,
and end-diastolic stress. Although there has yet to be a large
randomized controlled trial of NP-guided therapy for acute
HF, there have been a number of studies of NP-guided
treatment for HF in the outpatient setting. Although many
of these studies have yielded equivocal and often controver-
sial results, it is generally accepted that there is some benefit,
especially in those under 75 years of age (6,7). It was my
opinion 2 years ago that what many of these studies lacked
was the “biomonitoring” necessary to allow aggressive up-
titration of therapy in an attempt to actually decrease the
NP levels that were supposed to be guiding therapy (8).
This, I believe, has been achieved by Januzzi et al. (6) in the
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Critical Diagnostics.PROTECT (Pro-BNP Outpatient Tailored Chronic Heart
Failure Therapy) study, in this issue of the Journal.
Although PROTECT has the weakness of being a
single-center, unblinded study, measurable criteria such as
NP level, quality of life, and ventricular function were
measured and significantly improved in the NP-guided arm.
The investigators are to be congratulated for strong adher-
ence to study protocol with consistent biomonitoring of
amino-terminal pro-BNP (NT-proBNP) levels, allowing
aggressive therapeutic efforts at NT-proBNP lowering.
Thus, since my last editorial, I believe that we can now be
confident that lowering NP levels is indeed possible (it
happened in PROTECT), is safe (the kidneys still work,
the blood pressure is fine), and may lead to more benefits
compared with simple nonbiomonitored up-titration of
therapies. PROTECT demonstrates the most robust low-
ering of NT-proBNP concentrations reported to date in any
trial, with more than 44% of the “guided” therapy arm
achieving goal values. This was reflected in the increased
number of office visits and more diligent drug titration in
the NT-proBNP–guided arm, something quite different
from prior trials.
One possible limitation of the PROTECT trial is the
generalizability of its results. The “intervention” was not
limited to providing to the “active” arm investigators with
NP levels (biomonitoring). It also comprised an intensive,
proactive implementation of treatment optimization steps,
eventually prompted or encouraged by reminders from the
study organization and steering committee. This kind of
proactive biomonitoring may be possible only within struc-
tured disease management programs. The patients were also
younger than in many other studies and therefore may have
tolerated medication increases better than older patients.
Finally, the sample size was small, and there was a relatively
brief duration of follow-up. Therefore, although the con-
cept is proven, extrapolation to the real world and daily
practice must still be demonstrated.
Toward a New Definition of the “Ideal” Biomarker
Morrow and de Lemos (9) proposed 3 criteria required for
a biomarker to be clinically useful. First, the assay should be
precise, accurate, and rapidly available to clinicians at a
relatively low cost. Second, the biomarker must provide
additional information that is not surmised from clinical
evaluation. Last, the absolute measured value should help in
clinical decision making. The results of PROTECT allow a
reasonable revision that takes into account both biomarker-
guided therapy and biomonitoring during treatment (Table 1).
The following are 2 still hypothetical examples in the
setting of acute HF whereby one might be able to take
advantage of biomarkers that are surrogates of abnormal
physiology or biochemistry, allowing us to potentially treat
with a specific agent that improves outcomes as levels of that
biomarker decrease.
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October 25, 2011:1890–2 Biomonitoring and Biomarker-Guided TherapyHigh-sensitivity troponins. Studies have demonstrated
hat patients with acute decompensated HF sometimes have
roponin elevations that are associated with poor prognosis
10–12). Representing, in part, myocyte necrosis from
ubendocardial ischemia, elevated troponins in acute HF are
seful only for risk stratification. The advent of new
roponin assays capable of detecting troponins in the range
f nanograms per liter represents a new opportunity (13). In
a recent trial in which serial sampling of high-sensitivity
troponin I in acute HF was obtained, 2 distinct phenotypes
were seen (12). Although admission high-sensitivity tro-
ponin I levels were similar between all patients, those with
rapidly rising levels during hospitalization had worse out-
comes than those who had little or no increases. One could
conceivably “target” such an increase in troponin in acute
HF with agents that specifically affect subcellular myocardial
ischemia and subsequent myocyte necrosis (e.g., ranolazine).
It may therefore become reasonable to believe that an acute
intervention that protects the heart from cell injury (as
targeted in patients with continuous increases in high-
sensitivity troponin) may have an effect on long-term
outcomes. Figure 1 demonstrates a purported effect of such
a drug compared with placebo, mitigating the troponin
elevation and perhaps improving morbidity and mortality.
Copeptin. In patients with HF, increased arginine vaso-
pressin (AVP) concentrations are associated with more
severe disease, making AVP an attractive target for therapy.
However, AVP is difficult to measure because of its in vitro
instability and rapid clearance. Copeptin, the C-terminal
segment of pre-provasopressin, is a stable and reliable
surrogate biomarker for serum AVP concentrations (14).
Copeptin was measured as part of the BACH (Biomarkers
in Acute Heart Failure) study (15). Data from secondary
analysis of the BACH study revealed increased 90-day
mortality, readmission, and emergency department visit
rates in patients with elevated copeptin levels. Although
patients with low sodium and elevated copeptin were at
significantly increased risk for 90-day mortality, copeptin
levels were independent of sodium levels (16). Therefore,
copeptin may be a better surrogate for AVP elevation and a
sensible pharmacophenomic that may be specifically tar-
geted by AVP antagonists in HF. Although AVP antago-
nists have been used to treat hyponatremia in the general
The Ideal BiomarkerTable 1 The Ideal Biomarker
2007 2011
Sensitive and specific Either highly sensitive (diagnosis) or highly
specific (treatment effect)
Reflects disease severity Reflects abnormal physiology or biochemistry
Correlates with prognosis Prognosis is most meaningful if level is
clinically actionable
Should aid in clinical
decision making
Should be used as a basis for specific
“biomarker-guided therapy”
Level should decrease after
effective therapy
“Biomonitoring” during treatment is an effective
surrogate of improvementpopulation with encouraging results, efforts to use them inpatients with HF were not as successful (17). The ACTI-
ATE (Acute Heart Failure Patients With High Copeptin
evels Treated With Tolvaptan Targets Increased AVP
ctivation for Treatment Efficacy) trial is a multicenter
tudy that will randomize patients admitted for acute HF to
olvaptan versus placebo on the basis of activation of the
VP axis (copeptin). The study is set to begin in 2012 and
epresents one of the first cases of partnering between the
harmaceutical (Otsuka American Pharmaceutical, Inc.,
ockville, Maryland) and diagnostic (Brahms-Thermo
isher, Waltham, Massachusetts) industries. If the study is
uccessful, it would not be farfetched to “biomonitor”
atients with chronic HF with copeptin measurements and
rovide intermittent tolvaptan therapy in those whose levels
ave risen from baseline.
Conclusions
This editorial does not condone using biomarkers as surro-
gate end points for phase 3 clinical trials. That pathway has
led to disaster in a number of trials (18). What it does
suggest is that undertaking and completing studies that use
a rigorous combination of biomarker guidance and
biomonitoring with solid surrogates such as the NPs can
lead to improvement in patient care. Kudos to Januzzi et al.
(6) for a valiant effort in this regard. The just completed
HABIT (Heart Failure Assessment With B-Type Natri-
uretic Peptide in the Home) study is testing the feasibility of
finger-stick NP tests in the home, possibly negating some of
the “burdensome” patient office visits. Although the NPs
come close to the new proposed definition of an ideal
marker, other biomarkers are sure to follow. Those that are
successful will likely either be sensitive diagnostic or specific
prognostic markers. The validation of some biomarkers as
Figure 1 Hypothetical Trial Using Troponin to Guide
Treatment in Acute Heart Failure
In a hypothetical study, patients with acute heart failure and either elevated
high-sensitivity troponin or early rising troponin would be randomized to an
anti-ischemic drug versus placebo. The figure speculates that successful treat-
ment will mitigate troponin elevation, while placebo would not. Adapted from
Xue et al. (11).
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Biomonitoring and Biomarker-Guided Therapy October 25, 2011:1890–2physiologic or biochemical surrogate markers that can be
used to both guide therapy and monitor the effects of that
therapy may lead to a better segmentation of the HF
syndrome into individual phenotypes (so-called pharmaco-
phenomics) on the basis of the likelihood of response to
specific therapies. Markers of acute kidney injury (neutro-
phil gelatinase–associated lipocalin) and myocyte necrosis
(high-sensitivity troponins), along with methods to assess
tissue water, are likely to facilitate this segmentation. This is
typically what personalized medicine is, as opposed to “one
size fits all” medicine, thus far the basis of our current
management of HF.
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